Modality
mRNA
MOA
PI3Ki
Target
CD47
Pathway
Incretin
UCRA
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
Feb 2018
→ Jul 2031
Phase 1Current
NCT08802504
2,030 pts·RA
2020-04→TBD·Not yet recruiting
NCT03764860
671 pts·RA
2018-02→2031-07·Completed
2,701 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-12-084mo agoEnrollment Complete· UC
2031-07-135.3y awayPh2 Data· RA
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1/2
Complet…
P1/2
Not yet…
Catalysts
Enrollment Complete
2025-12-08 · 4mo ago
UC
Ph2 Data
2031-07-13 · 5.3y away
RA
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08802504 | Phase 1/2 | RA | Not yet recr... | 2030 | ORR |
| NCT03764860 | Phase 1/2 | RA | Completed | 671 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| BMR-1165 | BioMarin | Phase 2 | CD47 |